July 17, 2018
Cardiomyopathy Treatment in Rodent Models – ADA 2018
At ADA 2018, we shared the latest data on our next generation type 2 diabetes (T2D) and obesity rodent models. This included our latest ZDSD rat studies, examining possible therapeutic approaches for cardiomyopathy with the presence of metabolic syndrome.
LEARN MORE
July 5, 2018
Personalized Cancer Immunotherapy
Precision medicine and immunotherapy are currently two of the hottest areas of cancer research. How can immuno-oncology ...
LEARN MORE
July 3, 2018
Custom Murine Tumor Homografts for Efficacy Assessment
Murine tumor homografts provide an immunotherapeutic efficacy testing platform with the strengths of GEMM paired with ...
LEARN MORE
June 28, 2018
Assessing Combination Therapies in Syngeneic Tumor Models
Combination immunotherapy could enhance the clinical benefits of monotherapies and overcome patient lack of response to ...
LEARN MORE
June 26, 2018
Why to Use Isotype Control Antibodies
Good experimental design is key to accurate and precise drug development. Isotype control antibodies, designed and ...
LEARN MORE
June 21, 2018
Immunocompetent Murine Models for Immunotherapy Assessment
Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model ...
LEARN MORE
June 19, 2018
DGAT2 Inhibition Doesn’t Affect Plasma Triglycerides, VLDL ApoB
In a new study published in Cell Metabolism, McClaren et al utilize a variety of translational models, including both mouse models and non-human primate (NHP) models of obesity, to explore a potential therapeutic target for dyslipidemia. Their study focused on the effects of DGAT2 inhibition on lipid metabolism and whole-body metabolic flux.
LEARN MORE
June 15, 2018
Mouse Models of Multiple Sclerosis
Multiple sclerosis is a chronic disease affecting the central nervous system, which has multiple stages and currently ...
LEARN MORE
June 12, 2018
Leveraging PDX Models for In Vitro and Ex Vivo Assays
Patient-derived xenografts (PDX) are the most predictive and translational xenograft models available for preclinical ...
LEARN MORE
June 7, 2018
Is an Approved NASH Therapy on the Way?
Non-alcoholic steatohepatitis (NASH) is an unmet medical need with no approved therapies and debilitating consequences ...
LEARN MORE
June 5, 2018
PDX and Personalized Medicine
We discussed patient-derived xenografts (PDX) previously, from how to establish the models to when to add them to preclinical drug development. Today, we’ll focus on why these models are so important within preclinical research and how they are used to advance development in personalized medicine.
LEARN MORE
May 31, 2018
Predictive Immuno-Oncology Studies with Humanized PDX
Patient-derived xenograft (PDX) models are typically immunodeficient and inappropriate for most immuno-oncology (I/O) ...
LEARN MORE
May 29, 2018
Webinar FAQ: PDX Models in Drug Discovery Assays
Patient-derived xenografts (PDX) are the most predictive and translational preclinical xenograft models available for ...
LEARN MORE
May 24, 2018
Webinar FAQ: Humanized PDX Models in Immuno-Oncology
Patient-derived xenografts (PDX) support highly translational preclinical oncology research, but were historically ...
LEARN MORE
May 22, 2018
Immuno-Oncology and the Microbiome at AACR 2018
CrownBio presented thirteen posters at AACR 2018, sharing our latest internal research into patient derived xenografts, ...
LEARN MORE
